References:
1. Diamond EL, Durham BH, Haroche J, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov . 2016;6(2):154-165.
2. Durham BH, Diamond EL, Abdel-Wahab O. Histiocytic neoplasms in the era of personalized genomic medicine. Curr Opin Hematol . 2016;23(4):416-425.
3. Ozkaya N, Dogan A, Abdel-Wahab O. Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms. Hematol Oncol Clin North Am . 2017;31(4):705-719.
4. Chakraborty R, Burke TM, Hampton OA, et al. Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis.Blood . 2016;128(21):2533-2537.
5. Zarnegar S, Durham BH, Khattar P, et al. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer . 2018;65(1).
6. Lee LH, Gasilina A, Roychoudhury J, et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight . 2017;2(3):e89473.
7. Durham BH, Lopez Rodrigo E, Picarsic J, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med . 2019;25(12):1839-1842.
8. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.Blood . 2016;127(22):2672-2681.
9. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A . 2013;110(15):5957-5962.
10. Jain P, Fierst TM, Han HJ, et al. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles. Oncogene . 2017;36(45):6348-6358.
11. Jain P, Silva A, Han HJ, et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget . 2017;8(49):84697-84713.
12. Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol . 2011;121(6):763-774.
13. Roth JJ, Santi M, Pollock AN, et al. Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas. Brain Pathol . 2015;25(2):182-192.
14. Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature . 2015;526(7574):583-586.
15. Okimoto RA, Lin L, Olivas V, et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A . 2016;113(47):13456-13461.
16. Peng SB, Henry JR, Kaufman MD, et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. Cancer Cell . 2015;28(3):384-398.
17. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res . 2011;17(5):989-1000.
18. Jacobsen E, Abla O, Visser J. Malignant Histiocytoses. In: Abla O, Janka G, eds. Histiocytic Disorders. Cham: Springer International Publishing; 2018:361-381.
19. Ceppi F, Abla O. Juvenile Xanthogranuloma and Related Non-LCH Disorders. In: Abla O, Janka G, eds. Histiocytic Disorders. Cham: Springer International Publishing; 2018:293-311.
20. Picarsic J, Jaffe R. Pathology of Histiocytic Disorders and Neoplasms and Related Disorders. In: Abla O, Janka G, eds. Histiocytic Disorders. Cham: Springer International Publishing; 2018:3-50.